트레비 테라퓨틱스(TRVI)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $14.95 (-1.71%), 시가총액 $2.06B, 52주 범위 $5.47 ~ $15.40.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc.
트레비 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
트레비 테라퓨틱스의 현재 주가는 $14.95 (-1.71%)입니다. XTS에서 실시간 시세와 차트를 확인할 수 있습니다.
트레비 테라퓨틱스의 시가총액은 약 $2.06B입니다.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary…